New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Palmitoyl Dipeptide-6

Pancragen vs Palmitoyl Dipeptide-6

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Skin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not applicable (topical)
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
0.005–0.05% in formulation
Frequency
Daily for 10–30 days
Once or twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Increases skin firmness and density
  • Stimulates fibronectin and collagen IV production
  • Strengthens the dermal-epidermal junction
  • Reduces skin sagging in mature skin
  • Improves skin texture and smoothness
  • Supports extracellular matrix integrity
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Generally well-tolerated
  • Rare mild skin irritation in sensitive individuals
  • No known systemic effects at cosmetic concentrations
Stacks With